Close Menu
    Facebook X (Twitter) Instagram
    ScoopSquare24
    • Home
    • News
    • AI
    • Crypto
    • Finance
    • Stocks
    Facebook X (Twitter) Instagram
    ScoopSquare24
    Home»News»Stocks»Morgan Stanley Downgrades Kering (PRTP) Stock Amid Gucci Turnaround Doubts
    Stocks

    Morgan Stanley Downgrades Kering (PRTP) Stock Amid Gucci Turnaround Doubts

    Oli DaleBy Oli DaleApril 13, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    TLDR

    • Morgan Stanley downgraded Kering from “overweight” to “equal-weight,” reducing the price target from €330 to €320.
    • Shares declined more than 3% Monday in response to the rating change.
    • Analysts noted the stock’s year-to-date outperformance has already captured most potential gains.
    • First-quarter 2026 sales at flagship brand Gucci are now expected to fall 6.2% — a steeper decline than previously anticipated.
    • The rating cut arrives just before Kering releases Q1 2026 results on April 14 and hosts its Capital Markets Day on April 16.

    Shares of Kering stumbled Monday after Morgan Stanley withdrew its bullish stance on the French luxury conglomerate, revising its outlook just ahead of critical financial disclosures.


    PPX.DE Stock Card
    Kering S.A., PPX.DE

    The investment bank shifted its recommendation from “overweight” to “equal-weight” while reducing its 12-to-18-month target from €330 to €320. The announcement sent shares tumbling more than 3% during trading.

    Morgan Stanley’s rationale centered on valuation: Kering had outpaced competitors including LVMH, Hermès, and Richemont by 300 to 1,700 basis points year-to-date. According to the firm, this significant advance has already captured the bulk of potential upside.

    “Our DCF implies 15% upside to the shares, which no longer translates into relative outperformance,” the bank stated in its research note.

    The shares peaked at €320.50 on January 12 before retreating approximately 16% through Monday’s session. A substantial 10.90% rally on February 10 — the period’s strongest single-day performance — was largely erased by consecutive declines of 5.04% and 6.35% on March 2 and 3.

    Gucci Remains the Core Challenge

    The iconic Italian label continues to pose the primary obstacle. Morgan Stanley’s updated forecast anticipates Gucci sales contracting 6.2% during Q1 2026, representing a deterioration from the previous 5% decline estimate. Looking ahead, analysts project Gucci revenue of €5.95 billion for full-year 2026, expanding to €7.67 billion by 2028.

    The firm characterized the situation candidly: “a classic case where improving buzz is running ahead of the hard numbers.” Channel feedback from European retailers revealed “early signs of improving brand buzz but little evidence yet of a meaningful commercial recovery.”

    The more pessimistic projection also reflects weaker first-quarter channel intelligence and Kering’s vulnerability to Middle Eastern geopolitical tensions, representing approximately 5% of consolidated revenue.

    Critical Timing and Forward Outlook

    The downgrade arrives at a pivotal juncture. Kering is scheduled to release Q1 2026 financial results on April 14, immediately followed by its Capital Markets Day on April 16. These presentations will determine whether management’s turnaround narrative resonates with investors.

    Morgan Stanley lowered its 2028 earnings per share projection by 4% to €15.97, though this remains 15% above the Visible Alpha consensus of €13.80. At current levels, the stock trades at approximately 17 times forward earnings.

    Analysts forecast group-wide revenue reaching €18.3 billion by 2028, representing roughly 25% growth from 2025’s €14.7 billion. Consolidated operating margins are expected to climb from 12.5% in 2026 to 18.4% by 2028.

    Morgan Stanley’s optimistic scenario targets €480, predicated on a Gucci super-cycle driving group margins to 25.9% in 2028. The pessimistic scenario envisions €175, assuming the brand’s new creative direction fails commercially. Current options pricing suggests approximately 28.9% probability of exceeding €320 within twelve months, versus 17.1% odds of dropping below €175.

    The firm identified two potential catalysts for upgrading: continued operational improvements under CEO Luca de Meo, appointed in September 2025, and tangible proof of Gucci’s commercial resurgence.

    Notably, Morgan Stanley had elevated Kering in October 2025, designating it among top European luxury picks while praising the sector’s “burst of creativity.” Monday’s action represents a complete reversal from that optimistic assessment.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Oli Dale
    • Website

    Related Posts

    Circle Internet (CRCL) Hit with Class Action Lawsuit Over $280M Drift Protocol Breach

    April 17, 2026

    JPMorgan Analysts Say CLARITY Act Could Pass Before Midterm Elections

    April 17, 2026

    Tom Lee Predicts Further Gains After April 2026 Market Records

    April 17, 2026
    Leave A Reply Cancel Reply

    Breaking News
    Blockonomi

    Crypto News Just Turned Bullish: Coinbase CEO Brian Armstrong Calls a $60,000 Bitcoin Bottom While DOGE Holders Move to Pepeto

    Blockonomi
    Jun 16, 2026 9:27 PM
    Parameter

    CervoMed (CRVO) Stock Soars 32% on $3 Million Director Purchase

    Parameter
    Jun 16, 2026 8:27 PM
    Blockonomi

    CervoMed (CRVO) Surges 32% as Director Purchases $3 Million in Shares

    Blockonomi
    Jun 16, 2026 8:24 PM
    Moneycheck

    CervoMed (CRVO) Surges 32% Following Director’s $3 Million Stock Purchase

    Moneycheck
    Jun 16, 2026 8:24 PM
    Parameter

    Moderna (MRNA) Stock Surges 9% Following Positive FDA Assessment of mRNA Flu Vaccine

    Parameter
    Jun 16, 2026 8:20 PM
    Blockonomi

    Moderna (MRNA) Stock Surges 9% Following Positive FDA Review of mRNA Flu Vaccine

    Blockonomi
    Jun 16, 2026 8:17 PM
    Moneycheck

    Moderna (MRNA) Stock Surges 9% After FDA Gives Positive Signal on mRNA Flu Vaccine

    Moneycheck
    Jun 16, 2026 8:17 PM
    Coincentral

    CervoMed (CRVO) Stock Jumps 32% After Director Buys $3M – Time to Buy?

    Coincentral
    Jun 16, 2026 8:14 PM
    Parameter

    Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade from Underperform

    Parameter
    Jun 16, 2026 8:13 PM
    Blockonomi

    Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade to Peer Perform

    Blockonomi
    Jun 16, 2026 8:10 PM
    Moneycheck

    Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade to Peer Perform

    Moneycheck
    Jun 16, 2026 8:10 PM
    Coincentral

    Moderna (MRNA) Stock Jumps 9% as FDA Clears Key Hurdle for mRNA Flu Shot

    Coincentral
    Jun 16, 2026 8:06 PM
    Coincentral

    Palantir (PLTR) Stock Falls 2% Even After Getting a Wall Street Upgrade

    Coincentral
    Jun 16, 2026 8:01 PM
    Blockonomi

    Anchorage Digital Unlocks New SWEEP Infrastructure for Institutions

    Blockonomi
    Jun 16, 2026 7:16 PM
    Parameter

    Alphabet (GOOG) Stock: Rises as Google Expands Android 17 Parental Controls

    Parameter
    Jun 16, 2026 7:13 PM
    Facebook X (Twitter) Instagram Pinterest
    ScoopSquare24

    Copyright © 2013 - 2026 Kooc Media Ltd. All rights reserved. Registered Company No.05695741
    Our Sites: FlowPresets / GardenBeast / GolfMonster / Blockonomi / Money Check / CoinCentral / Parameter / Circlo / Computing.net

    Type above and press Enter to search. Press Esc to cancel.